To evaluate the roles of iatrogenic hypoglycemia and diabetes per se in the pathogenesis of defective hormonal counterregulation against hypoglycemia in insulin-dependent diabetes mellitus (IDDM), nondiabetic, and spontaneously diabetic BB/ Wor rats were studied using a euglycemic/hypoglycemic clamp. In nondiabetic rats, recurrent (4 wk) insulin-induced hypoglycemia (mean daily glucose, MDG, 59 mg/dl) dramatically reduced glucagon and epinephrine responses by 84 and 94%, respectively, to a standardized glucose fall from 110 to 50 mg/dl. These deficits persisted for > 4 d after restoring normoglycemia, and were specific for hypoglycemia, with normal glucagon and epinephrine responses to arginine and hypovolemia, respectively. After 4 wk of normoglycemia, hormonal counterregulation increased, with the epinephrine, but not the glucagon response reaching control values. In diabetic BB rats (MDG 245 mg/dl with intermittent hypoglycemia), glucagon and epinephrine counterregulation were reduced by 86 and 90%, respectively. Chronic iatrogenic hypoglycemia (MDG 52 mg / dl) further suppressed counterregulation. Prospective elimination of hypoglycemia (MDG 432 mg/dl) improved, but did not normalize hormonal counterregulation. In diabetic rats, the glucagon defect appeared to be specific for hypoglycemia, whereas deficient epinephrine secretion also occurred during hypovolemia. We concluded that both recurrent hypoglycemia and the diabetic state independently lead to defective hormonal counterregulation. These data suggest that in IDDM iatrogenic hypoglycemia magnifies preexisting counterregulatory defects, thereby increasing the risk of severe hypoglycemia. (J. Clin. Invest. 1993. 92:2667-2674
Introduction
Symptomatic hypoglycemia is a common complication in the treatment of insulin-dependent diabetes mellitus (IDDM ). ' The incidence of severe episodes of hypoglycemia resulting in seizure or coma, or requiring another individual to administer therapy, is increased two-to threefold in patients practicing intensive insulin therapy ( 1, 2). This phenomenon has become the principal factor limiting the attainment of normoglycemia in IDDM, thereby frustrating attempts to diminish the complications associated with long-standing diabetes (3) (4) (5) (6) (7) .
Although hypoglycemia in IDDM is mediated in part by overinsulinization, it is now appreciated that a deficient hormonal counterregulatory response to hypoglycemia is a key pathogenic factor (8) (9) (10) (11) (12) . IDDM patients lose their capacity to release glucagon during hypoglycemia relatively early in the course of the disease ( 13) , and as a result, are dependent on epinephrine to reverse hypoglycemia (14) (15) (16) (17) . Unfortunately, many IDDM patients lose their epinephrine counterregulation as well, and therefore are particularly vulnerable to severe hypoglycemia (5, 13) . Intensive insulin treatment regimens de- signed to achieve near normoglycemia in IDDM also suppress the epinephrine response to hypoglycemia, thereby compounding the problem of deficient counterregulation and increasing the risk of hypoglycemia (3, 18, 19) . Recent studies suggest that this effect of intensive insulin treatment may be due, at least in part, to hypoglycemia itself (3, 20) . Heller et al.
(2 1 ) have reported that one episode of antecedent hypoglycemia may blunt glucagon and epinephrine secretion in humans. The impact ofrecurrent hypoglycemia remains uncertain. Furthermore, it is not known whether the suppression of counterregulatory hormone release persists after return to normoglycemia, and whether such effects are stimulus specific for hypoglycemia.
The aims of this study were to determine (a) the influence of recurrent insulin-induced hypoglycemia, independent of diabetes, on hormonal counterregulation in nondiabetic BB rats; (b) the time course for recovery of defective counterregulation after restoration of normoglycemia; (c) the stimulus specificity of the hormonal defect induced by recurrent hypoglycemia; and (d) the contribution of recurrent hypoglycemia to, and the stimulus specificity of deficient hormonal counterregulation observed in IDDM.
Methods

Animals.
Male nondiabetic and autoimmune, spontaneously diabetic BB rats were supplied by the BB/Wor lab (University of Massachusetts, Worcester, MA) (22) (23) (24) (25) . Nondiabetic BB rats were members of the "diabetes resistant" strain of BB rats, of which less than 1% develop diabetes (26). 10 groups of rats were studied; their treatment data are summarized in Table I . For each group, the mean glucose during insulin treatment was determined in the fed state by measuring plasma glucose from the tail vein at least four times during a 24-h cycle on at least three different days, and often more frequently, to adequately determine the extent of the diurnal glycemic response to each insulin treatment, including the times of the greatest probability of hypoglycemia, normoglycemia, or hyperglycemia. The influence of recurrent insulin-induced hypoglycemia, independent of diabetes, on hormonal counterregulation was examined in two groups of nondiabetic rats using the hyperinsulinemic euglycemic/hypoglycemic clamp. Group I consisted of nondiabetic rats aged 4 mo that had a mean glucose of 120± 10 mg/dl (mean±SD), and served as controls. Group II were nondiabetic rats that at 3-4 mo ofage were made recurrently hypoglycemic using a gradually increasing protamine zinc iletin (PZI; Eli Lilly & Co., Indianapolis, IN) insulin dose regimen over 5 d, followed by 3-4 wk of treatment with twice-daily injections of -8-9 U/kg PZI insulin (mean glucose 59±21 mg/dl).
Aim 2. The time course for recovery of deficient hormonal counterregulation after recurrent hypoglycemia was assessed in two groups of recurrently hypoglycemic nondiabetic rats that were treated similarly to group II. These animals underwent euglycemic/hypoglycemic clamp studies at 3-6 d (group III) or 3-4 wk (group IV) after discontinuation of insulin treatment and restoration of normoglycemia.
Aim 3. The stimulus specificity of the hormonal defect induced by recurrent hypoglycemia was evaluated by quantitating glucagon and epinephrine responses to arginine infusion and hypovolemic stress, respectively, in two groups of nondiabetic rats during a euglycemic clamp. Group V were nondiabetic rats similar to group I that served as controls. Group VI were similar to group III, nondiabetic rats made chronically hypoglycemic for 3-4 wk and then allowed to recover to normoglycemia for 4 d before the experiment.
Aim 4. The contribution of recurrent hypoglycemia to deficient counterregulation observed in IDDM was examined using the euglycemic/hypoglycemic clamp in three groups of animals from a rat model of IDDM (diabetic BB rats), in whom the insulin treatment regimen was varied to produce differing degrees ofglycemic control and antecedent hypoglycemia. Group VII were diabetic rats treated from the onset of diabetes (age of onset -2.5 mo) for 6-8 wk with a standard daily injection regimen of 8 U/kg PZI insulin. This treatment produced intermediate control as reflected by a mean glucose of245±180 mg/dl. Glucose monitoring revealed that this group had intermittent episodes of hypoglycemia lasting several hours per day. Groups VIII and IX were initially treated in the same manner as group VII, and then were prospectively switched to insulin regimens designed to achieve chronic hypoglycemia (group VIII), or to eliminate antecedent hypoglycemia (group IX), for 3-4 wk. Group VIII received two daily injections of 7 U/kg PZI for 3-4 wk (mean glucose 52±19 mg/dl). Group IX received two daily injections of 1.6-2 U/kg PZI that resulted in a mean glucose of 432±106 mg/dl without episodes of hypoglycemia detected by frequent monitoring throughout the 24-h diurnal cycle during the 3-4 wk treatment (dubbed "poor control"). The stimulus specificity of the counterregulatory defects in diabetes was studied in a similar group of poorly controlled diabetic rats (group X) using the arginine infusion and hypovolemic stress protocol. The use of poorly controlled diabetic rats avoided the potentially confounding effect of antecedent hypoglycemia on hormonal responses.
Experimental procedures Euglycemic/hypoglycemic clamp. The hyperinsulinemic glucoseclamp technique, as adapted for the rat (27) , was used to provide a fixed hypoglycemic stimulus to rats in groups I to IV and VII to IX. At least 3 d before the experiment, under pentobarbital anesthesia, catheters were inserted into a carotid artery for blood sampling and one or two jugular veins for infusion oftest substances, and filled with a heparin/polyvinylpyrrolidone solution, as previously described (27) . The catheters were fastened to skin on the rat's back with tape and surgical staples. The rats were fasted for -16 h before the study. On the day of the study, the heparin/polyvinylpyrrolidone solution was withdrawn and the catheters were infused with heparinized saline ( -25 ,l/min) for at least 30 min before the experiment. The rats were conscious, unstressed, and allowed to roam freely in their cage during the experiment. At the outset, a primed (360 mU over 1.5 min)-constant insulin infusion [20 mU/(kg * min)] was begun and a variable infusion of exogenous glucose was adjusted based on plasma glucose measurements obtained at 5-min intervals to achieve the desired glucose level. During the first 90 min of the experiment, the rats were brought to euglycemia (mean plasma glucose -110 mg/dl). Thereafter, plasma glucose was allowed to fall to hypoglycemic levels (-50 mg/dl) and was maintained for 90 min. Experiments were terminated ifthe plasma glucose fell below 80 mg/dl during the last 45 min of the euglycemic phase, or rose above 70 mg/dl (secondary to glucose infusion), or inadvertently fell below 35 mg/dl during the hypoglycemic phase. Because a supraphysiologic insulin infusion rate of20 mU/(kg -min) was necessary to induce a hypoglycemic stimulus of50 mg/dl in the nondiabetic controls, this insulin infusion was used in all groups (except group IX). The chronically hyperglycemic rats (group IX) were more insulin resistant, and thus this group received a higher insulin dose [50 mU/ (kg. min)] to achieve the appropriate level of hypoglycemia.
Blood samples for measurement ofglucagon and epinephrine were taken during the baseline period and during the euglycemic (75 and 90 min) and hypoglycemic ( 120, 135, 150, 165, and 180 min) portions of the experiments. Blood obtained from nondiabetic BB rats at least 30 min before the experiment was transfused during the experiment to quantitatively replace blood withdrawn during the study.
Arginine infusion/hypovolemic stress study. To assess glucagon and epinephrine secretion to a nonhypoglycemic stimulus (groups V, VI, and X), arginine infusion and hypovolemic stress were sequentially administered while maintaining a euglycemic ( 1 10 mg/dl), hyperinsulinemic [20m U/(kg. min)] clamp throughout the study using a variable glucose infusion. The first 90 min ofthe experiment were identical to the euglycemic portion of the euglycemic/hypoglycemic clamp described above. However, at 90 min, an arginine infusion [30 mg/(kg min), pH * 7.4] was superimposed for 60 min (28) . At 150 min, arginine infusion and blood replacement were discontinued and 10 mg/kg of blood was withdrawn to initiate the hypovolemic stress phase of the study. Subsequently, 5 ml/kg of blood was withdrawn (and not replaced) every 15 min for -75 min.
Blood samples for measurement ofglucagon and epinephrine were taken at the baseline and at the end of the euglycemic phase of the experiment. During the arginine infusion, glucagon was determined at 1 5-min intervals. Epinephrine measurements were obtained before the hypovolemic stress (at 150 min), and every 15 min thereafter during the hypovolemic phase of the study.
Analytic procedures. Plasma glucose was measured by the glucose oxidase method (Beckman Instrs., Inc., Fullerton, CA). Glucagon (ICN Biomedicals, Inc., Costa Mesa, CA) and insulin (Binax, South Portland, ME) levels were measured by a double antibody RIA, while catecholamines were assayed using a radioenzymatic assay (Amersham Corp., Arlington Heights, IL).
Calculations. Mean plasma glucose levels during the euglycemic phase were calculated from the interval 45 to 90 min, during the hypoglycemic phase from 105 to 180 min, during the arginine infusion from 95 to 150 min, and during the hypoglycemic stress from 155 min to the end of the study. Peak glucagon and epinephrine responses to acute hypoglycemia represent the difference between maximal hypoglycemic values (the mean of the two greatest values during hypoglycemia) and mean euglycemic values. Glucagon and epinephrine responses during the sequential arginine infusion/hypovolemic stress study were calculated by subtracting the prestimulus values from the mean of the two greatest values during arginine infusion or hypovolemic stress.
Data are reported as the mean or as the mean±SE, except for data for mean treatment glucose, which are reported as mean±SD. Comparisons between two groups were performed using the two-tailed Student's t test, or between three or more groups using ANOVA.
Results
The effect of, and recoveryfrom, recurrent hypoglycemia in nondiabetic rats (groups I to IV). Mean glucose levels for the control and each recurrent hypoglycemia group were not significantly different during the euglycemic ( 1 1±12, 112±2, 1 10+1, and 1 13±2 mg/dl) and hypoglycemic (52±1, 50±1, 52±2, and 55±2 mg/dl, respectively for groups I, II, III, and IV) phases of the experiment. The effects of recurrent hypoglycemia on hormonal counterregulation in nondiabetic rats studied with the hyperinsulinemic euglycemic/hypoglycemic clamp are depicted in Fig. 1 , and peak hormonal responses are summarized in Table II . In nondiabetic rats studied immediately after 3-4 wk of recurrent hypoglycemia (group II), peak glucagon and epinephrine responses during the hypoglycemic phase of the clamp were reduced by 84 (P < 0.0001) and 94% (P < 0.001), respectively, when compared to the untreated, nondiabetic controls (group I). 3-6 d after restoration of normoglycemia (group III), suppression of hormonal counterregulation persisted, i.e., the responses remained indistinguishable from those immediately after the hypoglycemic treatment (P = NS vs group II). However, 3-4 wk after restoration ofnormoglycemia (group IV), the epinephrine and glucagon responses increased significantly, rising 11-fold (P < 0.01, Fig. 1 c) and 3-fold (P < 0.05, Fig. 1 groups I to IV) were higher in both groups III and IV than in group I (P <0.05).
Stimulus specificity ofhormonal defects in nondiabetic rats (groups V, VI). Mean glucose levels for the nondiabetic control (V) and 4-d post-hypoglycemia (VI) groups were maintained at euglycemia before (11 1±3 and 109±1 mg/dl) and during the arginine infusion (107±3 and 114±4 mg/dl, respectively). Plasma glucose rose slightly during the hypovolemic stress phase of the experiment (116±2 and 126±5 mg/dl, respectively), however, these changes did not reach statistical significance. Plasma insulin concentrations during the clamps were not significantly different in groups V (751±279 ,uU/ml) and VI (1100±64 tiU/ml). The glucagon responses to arginine infusion (during which the epinephrine values remained at baseline) and the epinephrine responses to hypovolemic stress in the nondiabetic controls (group V) and in the nondiabetic rats recovering from recurrent hypoglycemia (group VI) are depicted in Fig. 2 . The hormonal responses to hypoglycemia of similar treatment groups are given for comparison in Fig. 2 (groups I and III). The glucagon and epinephrine responses to acute hypoglycemia (Fig. 2, b and d ) in rats studied after 3-6 d of recovery from recurrent hypoglycemia (group III) were suppressed. In marked contrast to the deficient responses to hypoglycemia in group III, both the glucagon response to arginine (Fig. 2 a) , and the epinephrine response to hypovolemia (Fig.  2 c) displayed by group VI were similar to those seen in untreated nondiabetic controls (P = NS vs group V).
The effects ofglycemic control on hormonal counterregulation in diabetic rats (groups VII to IX). The effects ofglycemic control on hormonal counterregulation in the diabetic BB rats during the euglycemic/hypoglycemic clamp experiments are shown in Fig. 3 and peak hormonal responses are summarized in Table II . Diabetic rats under intermediate control (group VII) had peak glucagon and epinephrine responses to hypoglycemia that were markedly reduced, by 86 (P < 0.0001, Fig. 3 b) and 90% (P < 0.001, Fig. 3 c) , respectively, compared to the nondiabetic controls (group I). This hormonal suppression occurred despite a slightly greater hypoglycemic stimulus in the diabetic group (46±1 mg/dl) than the nondiabetic controls (52±1 mg/dl, P < 0.01). Plasma insulin levels during the clamp experiments were comparable (715±110 and 657±62
,U/rnl, respectively for groups I and VII (Fig. 2 a) tended to be slightly less, but not significantly different than that in the nondiabetic controls (P > 0.20 vs group V), in contrast to the markedly blunted response to hypoglycemia (Fig. 2 b) . On the other hand, much like the blunted epinephrine response to hypoglycemia in this group (Fig. 2 d) , the epinephrine response to hypovolemia (Fig. 2 c) (20, 21) . However, those studies did not establish whether the effect is (a) persistent or counterbalanced by adaptation chronically, and (b) specific for hypoglycemic stimuli.
In the current studies we examined the effect of more prolonged periods of recurrent hypoglycemia on hormonal counterregulation. Rats were chosen as an experimental model because of(a) the high morbidity ofchronic recurrent hypoglycemia; (b) the ability to monitor, manipulate, and ensure compliance with different treatment regimens; (c) the ability to provide a significant and standardized hypovolemic stress stimulus for assessing the specificity of defective epinephrine secretion; and gan physiologic experimentation after the characterization of the models herein. The diabetic BB rat was used because this animal model develops spontaneous, autoimmune, insulin-dependent diabetes that bears a striking resemblance to type I diabetes in humans, though more rapid in onset (22) (23) (24) (25) . Moreover, the diabetic BB rat provided us with an opportunity to characterize the in vivo counterregulatory response of an animal model oftype I diabetes free ofthe potentially multiple confounding toxic effects, and often incomplete diabetes, inherent in the use of alloxan or streptozotocin (32) .
The hyperinsulinemic, euglycemic/hypoglycemic clamp technique was used to control glucose levels and provide a standardized, fixed hypoglycemic stimulus. During the arginine infusion/hypovolemic stress experiments, the clamp technique was used to reproduce the supraphysiologic hyperinsulinemia accompanying the hypoglycemia study while fixing glucose levels at baseline values. This approach diminished the confounding effect of varying hyperglycemia on hormone secretion in response to arginine infusion and hypovolemic stress, thus providing a more accurate comparison of the effects of each treatment on responses to the different stimuli.
The current studies demonstrate a profound defect in hormonal counterregulation following a 3-4-wk period of recurrent hypoglycemia in nondiabetic rats (Fig. 1) . Immediately after treatment, the glucagon and epinephrine response to hypoglycemia decreased 84 and 94%, respectively, relative to control values (Table II) . This defect persisted, without significant change, even after 3-6 d ofrecovery. The epinephrine, and to a lesser extent the glucagon, response to hypoglycemia began to increase 1-2 wk after restoration of normoglycemia (results not shown). By 3-4 wk after treatment, the epinephrine response had fully recovered, and the glucagon response had increased significantly, but still remained significantly less than the untreated nondiabetic control (Fig. 1) . These findings imply that the hormonal defects produced by recurrent hypoglycemia are persistent, but reverse over time. It is possible that a more prolonged recovery from antecedent hypoglycemia would have further restored glucagon counterregulation.
To determine whether the deficient hormonal counterregulation subsequent to recurrent hypoglycemia was stimulus specific, nonhypoglycemic stimuli for glucagon (arginine infusion) and epinephrine secretion (hypovolemic stress) were administered to nondiabetic rats 4 d after restoration of normoglycemia. Rats 4 d after hypoglycemic treatment were used because of the stability of their metabolic state (i.e., absence of recent hypoglycemia), while their hormonal counterregulatory response to acute hypoglycemia remained maximally suppressed. Interestingly, these rats exhibited completely normal glucagon and epinephrine secretory responses to nonhypoglycemic stimuli (Fig. 2) , indicating that the secretory reserves ofthe a-cells and adrenal medulla were intact and that the persistent hormonal defects induced by recurrent hypoglycemia were not due to glandular hormonal depletion. Instead, our data suggest that recurrent hypoglycemia itself, independent of diabetes, blunts hormonal responses specifically to hypoglycemic stimuli.
The role of recurrent hypoglycemia in the deficient counterregulation observed in IDDM was also investigated using BB rats 6-8 wk after diabetes onset that were receiving a standard insulin regimen (Fig. 3) . These rats displayed a striking (85-90%) diminution of their glucagon and epinephrine responses to hypoglycemia (Table II) . It is noteworthy that although these diabetic rats had a mean glucose of245 mg/dl, they experienced intermittent episodes of hypoglycemia averaging several hours in duration daily. To examine the contribution of recurrent hypoglycemia to their deficient counterregulation, we studied diabetic rats treated initially by the standard insulin regimen and then prospectively switched to either chronic hypoglycemia (mean glucose = 52±19 mg/dl) or elimination of antecedent hypoglycemia (mean glucose = 432±106 mg/dl). As in the nondiabetic rats, chronic hypoglycemia further decreased the glucagon and epinephrine responses to acute hypoglycemia. In contrast, elimination of the hypoglycemic episodes seen in the intermediate control group for 3-4 wk caused a fourfold increase in the epinephrine response to near normal levels, and a more modest increase in the glucagon response to acute hypoglycemia, demonstrating the malleability ofthe hormonal counterregulation in diabetes and its dependence on the level of antecedent glycemia. However, even with elimination of antecedent hypoglycemia, the peak glucagon and epinephrine responses by the diabetic rats remained significantly reduced by 75 and 53%, respectively, relative to the nondiabetic controls. It is possible that a more prolonged period free from hypoglycemia would have further increased hormonal counterregulation. It should be noted that insulin levels, by necessity, were significantly higher in the poorly controlled diabetic group (IX). Thus, it is conceivable that more pronounced hyperinsulinemia during the experiments in the poorly controlled diabetic rats contributed in part to the suppression of glucagon and epinephrine release observed in these studies. Smaller, though significant, increases in insulin levels were also observed in groups III and IV despite identical infusion rates, so that the hormonal responses of these nondiabetic rats after 4 d and 4 wk of recovery from recurrent hypoglycemia may have been closer to the controls if we had achieved lower insulin levels. However, previous studies have demonstrated that a two-to fourfold variation in insulin concentration has little or no effect on hormonal counterregulation (33) (34) (35) (36) . The influence of more pronounced insulin differences, on the other hand, remains unclear, with both suppression and augmentation of hormone secretion reported with 8-10-fold variations in insulin levels (37, 38) . These reports (37, 38) compared supraphysiologic with low-to-mid-physiologic hyperinsulinemia, a range in which the greatest effect is likely to be observed. In our study, insulin levels were by necessity supraphysiologic in all groups (> 600 AU/ml), and the relative differences in insulin levels between groups were small, making it unlikely that differences in insulin concentrations between the groups contributed to any differences seen in hormonal counterregulation. On the other hand, the large doses of insulin used in these studies potentially limit the clinical application of our data.
We next investigated whether the blunted hormonal counterregulation that persisted despite elimination of antecedent hypoglycemia in the diabetic rats was specific for hypoglycemic stimuli. Previous studies in human IDDM have found an increased glucagon response to arginine (39) (40) (41) (42) , which decreases to normal values if insulin is administered concomitantly (41, 42). However, those studies did not control the plasma glucose or insulin concentrations during the experiment, and did not treat nondiabetic controls with similar insulin infusions. Histologic studies in treated or stable diabetic BB rats have found normal islet glucagon content (22, 43, 44) , but the in vivo glucagon response to intravenous arginine infusion in the diabetic BB rat has not been adequately studied. In the current study, diabetic rats after 3-4 wk without hypoglycemia were used to eliminate the effect of antecedent hypoglycemia on the results. While the glucagon response to arginine infusion in the diabetic group tended to be less, it was not significantly different from that in the nondiabetic controls. However, it is possible that the lack of a significant difference represents a type II error due to the large variation in the response of the nondiabetic controls. The diabetic's response suggests a minimal reduction in a-cell secretory reserve or function. This small change could reflect a relatively greater inhibition ofglucagon secretion in the diabetic rat by supraphysiologic hyperinsulinemia. The similarity of the experimental conditions during administration ofarginine or hypoglycemic stimuli allows a more valid comparison ofglucagon responses to different stimuli. In this case, defective glucagon secretion appears to be restricted to hypoglycemic stimuli in the diabetic rat.
Previous studies examining epinephrine secretion in IDDM have been limited by the difficulty of providing a standardized epinephrine stimulus. It has been reported that humans with diabetes have epinephrine responses to exercise that are similar or greater than those in nondiabetics, even when the diabetics exhibit a deficient epinephrine response to acute hypoglycemia (45) . However, the exercise protocol (45) produced only a 20-50% increase in epinephrine for nondiabetics, compared to a 600% increase in response to hypoglycemia. Thus, the exercise provided a relatively mild stimulus for epinephrine secretion, inadequate to assess the specificity of a hormonal deficit. We used gradual blood volume depletion on a volume per unit weight basis to provide quantitatively similar stimuli within and between groups of rats. Glucose was fixed at euglycemic levels using a hyperinsulinemic clamp to eliminate the confounding effect of different degrees of ensuing hyperglycemia on epinephrine release. In contrast to the stimulus specificity ofthe glucagon deficit, the epinephrine response to hypovolemic stress in the diabetic BB rat was markedly reduced by 78% relative to the nondiabetic controls' response. This observation suggests that the disturbance in adrenomedullary function seen in the diabetic BB rat is nonspecific in nature. Interestingly, the defect develops over a relatively short period; rats had been diabetic for a total ofonly 9-10 wk. Whether this nonspecific dysfunction is a consequence ofthe neuropathic effects of poorly controlled diabetes or due to autoimmune adrenalitis is uncertain. Although the poorly controlled rats had free access to water and maintained their weight, it is possible that a subtle degree of chronic hypovolemia decreased their response to acute hypovolemia.
To the extent that our findings are relevant in the clinical setting, they have important implications for the treatment of type I diabetics. In as much as patients with type I diabetes have almost completely absent glucagon response to hypoglycemia, epinephrine must partially counterbalance the glucagon deficit and become the primary counterregulatory hormone. As recurrent hypoglycemia profoundly diminishes epinephrine counterregulation, those diabetics experiencing recurrent hypoglycemia will have lost their last remaining acute counterregulatory mechanism. In an attempt at maintaining tighter glycemic control with the aim of reducing the long-term vascular and neural complications of diabetes, the morbidity from hypoglycemia may be increased greatly. Extrapolating the results in our rat studies to humans, antecedent hypoglycemia diminishes future glucagon and epinephrine responses to hypoglycemia, so that hypoglycemia begets hypoglycemia. Furthermore, decreased hormonal counterregulation makes future episodes of hypoglycemia not only more likely, but also more severe, especially for those individuals with hypoglycemia unawareness (46). A similar scenario has been suggested by Cryer et al. based on studies after one episode of hypoglycemia in humans (21, 46 ). The effect of antecedent hypoglycemia to diminish the sympathetic response to acute hypoglycemia may also make hypoglycemia more difficult to detect by the patient, contributing to the syndrome ofhypoglycemia unawareness (47).
The stimulus specificity of the deficient glucagon and epinephrine responses of nondiabetic rats to acute hypoglycemia has implications for the nature ofthe defect(s) caused by antecedent hypoglycemia. In analysis of his results from nondiabetic humans, Cryer suggested that antecedent hypoglycemia causes a hypoglycemia-associated autonomic failure, and in turn induces the counterregulatory defects seen after recurrent hypoglycemia (47). However, our results do not support this view. We observed a completely normal epinephrine response to hypovolemia, despite the near absence ofa response to hypoglycemia in nondiabetic rats studied 4 d after recurrent hypoglycemia, suggesting that the adrenal medulla and the sympathetic pathways involved in autonomic activation of the adrenal medulla remain intact.
In summary, we examined the effect ofrecurrent hypoglycemia on glucagon and epinephrine counterregulation, and the persistence and stimulus specificity of deficient hormonal counterregulation after recurrent hypoglycemia in nondiabetic and diabetic BB rats. We found that (A) recurrent hypoglycemia results in profound defects in hormonal counterregulation independent of diabetes. (B) These defects are persistent for at least 4 d after return to normoglycemia. (C) Both glucagon and epinephrine counterregulation increase significantly after 4 wk of recovery from hypoglycemia, with the epinephrine, but not the glucagon, response returning to normal levels. (D) The effect of recurrent hypoglycemia to blunt hormone secretion is stimulus specific for hypoglycemia. (E) The effect of recurrent hypoglycemia to profoundly diminish hormonal counterregulation extends to IDDM. However, diabetes, independent of antecedent hypoglycemia, leads to blunted glucagon and epinephrine counterregulation. (F) In the diabetic rat, glucagon secretion is diminished specifically to glycemic stimuli, but epinephrine secretion is nonspecifically diminished. These data indicate that both the diabetic state and recurrent hypoglycemia independently impair hormonal counterregulation in the BB rat. Our data suggest that in IDDM, iatrogenic hypoglycemia magnifies preexisting counterregulatory defects, thereby increasing the risk of severe hypoglycemia.
